Market Closed -
OTC Markets
15:29:14 10/05/2024 BST
|
5-day change
|
1st Jan Change
|
0.444
USD
|
0.00%
|
|
0.00%
|
-83.80%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
7.669
|
4.183
|
26.22
|
35.01
|
31.19
|
Enterprise Value (EV)
1 |
7.582
|
3.919
|
26.22
|
34.8
|
31.18
|
P/E ratio
|
-11.8
x
|
-10.9
x
|
-34.2
x
|
-149
x
|
-30.9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
10,326,885
x
|
-
|
-
|
-
|
-
|
EV / Revenue
|
10,210,629
x
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-3.89
x
|
-3.91
x
|
-35.7
x
|
-114
x
|
-50.8
x
|
EV / FCF
|
-6,743,356
x
|
-3,408,262
x
|
1,079,429,283
x
|
-109,546,985
x
|
-2,713,732,852
x
|
FCF Yield
|
-0%
|
-0%
|
0%
|
-0%
|
-0%
|
Price to Book
|
-102
x
|
89
x
|
-57.4
x
|
-325
x
|
-32.8
x
|
Nbr of stocks (in thousands)
|
2,789
|
2,789
|
17,483
|
17,507
|
31,189
|
Reference price
2 |
2.750
|
1.500
|
1.500
|
2.000
|
1.000
|
Announcement Date
|
12/02/20
|
30/03/20
|
17/09/21
|
16/03/22
|
14/04/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
|
-
|
0.7426
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-3.055
|
-1.948
|
-1.003
|
-0.7344
|
-0.3055
|
-0.6133
|
EBIT
1 |
-3.234
|
-2.202
|
-1.034
|
-0.7658
|
-0.3369
|
-0.6446
|
Operating Margin
|
-
|
-296.55%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-3.234
|
-2.202
|
-1.034
|
-0.7658
|
-0.2369
|
-0.9848
|
Net income
1 |
-3.234
|
-2.202
|
-1.41
|
-0.7658
|
-0.2369
|
-0.9848
|
Net margin
|
-
|
-296.55%
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.5356
|
-0.2328
|
-0.1377
|
-0.0438
|
-0.0134
|
-0.0323
|
Free Cash Flow
|
-
|
-1.124
|
-1.15
|
0.0243
|
-0.3176
|
-0.0115
|
FCF margin
|
-
|
-151.42%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/02/20
|
12/02/20
|
30/03/20
|
17/09/21
|
16/03/22
|
14/04/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
0.55
|
0.09
|
0.26
|
0
|
0.22
|
0.01
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-1.12
|
-1.15
|
0.02
|
-0.32
|
-0.01
|
ROE (net income / shareholders' equity)
|
-
|
2,133%
|
-4,283%
|
1,041%
|
83%
|
184%
|
ROA (Net income/ Total Assets)
|
-
|
-147%
|
-86.5%
|
-86.8%
|
-42.2%
|
-121%
|
Assets
1 |
-
|
1.499
|
1.63
|
0.882
|
0.5616
|
0.8144
|
Book Value Per Share
2 |
0.0100
|
-0.0300
|
0.0200
|
-0.0300
|
-0.0100
|
-0.0300
|
Cash Flow per Share
2 |
0.0900
|
0.0100
|
0.0200
|
0
|
0.0100
|
0
|
Capex
1 |
0
|
0.04
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
5.12%
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/02/20
|
12/02/20
|
30/03/20
|
17/09/21
|
16/03/22
|
14/04/23
|
|
1st Jan change
|
Capi.
|
---|
| -83.80% | 14.24M | | +29.77% | 49.18B | | +1.00% | 42.11B | | +50.47% | 40.37B | | -5.26% | 28.85B | | +13.68% | 26.09B | | -22.99% | 18.71B | | +8.22% | 13.26B | | +32.41% | 12.32B | | -1.62% | 11.99B |
Other Biotechnology & Medical Research
|